MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200...
MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature
About this item
Full title
Author / Creator
Jarius, S. , Ruprecht, K. , Stellmann, J. P. , Huss, A. , Ayzenberg, I. , Willing, A. , Trebst, C. , Pawlitzki, M. , Abdelhak, A. , Grüter, T. , Leypoldt, F. , Haas, J. , Kleiter, I. , Tumani, H. , Fechner, K. , Reindl, M. , Paul, F. and Wildemann, B.
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Antibodies to human full-length myelin oligodendrocyte glycoprotein (MOG-IgG) as detected by new-generation cell-based assays have recently been described in patients presenting with acute demyelinating disease of the central nervous system, including patients previously diagnosed with multiple sclerosis (MS). However, only limited data are availab...
Alternative Titles
Full title
MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_35a6f708ff424e5f82891ba67eebc0a0
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_35a6f708ff424e5f82891ba67eebc0a0
Other Identifiers
ISSN
1742-2094
E-ISSN
1742-2094
DOI
10.1186/s12974-018-1108-6
